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Side chain fluorination is often used to make analogs
of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] resistant
to degradation by 24-hydroxylase. The fluorinated
nonsteroidal analogs CD578, WU515, and WY1113
have an increased prodifferentiating action on
SW480-ADH colon cancer cells, which correlated
with stronger induction of vitamin D receptor (VDR)-
coactivator interactions and stronger repression of
b-catenin/TCF activity. Cocrystallization of analog
CD578 with the zebrafish (z)VDR and an SRC-1 coac-
tivator peptide showed that the fluorine atoms of
CD578 make additional contacts with Val444 and
Phe448 of activation helix 12 (H12) of the zVDR and
with Leu440 of the H11-H12 loop. Consequently, the
SRC-1 peptide makes more contacts with the VDR-
CD578 complex than with the VDR-1,25(OH)2D3 com-
plex. These data show that fluorination not only
affects degradation of an analog but can also have
direct effects on H12 stabilization.
INTRODUCTION
1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the most active form of
vitamin D3, binds to the vitamin D receptor (VDR), a member of the
nuclear receptor superfamily, which dimerizes with the retinoid X
receptor (RXR). These heterodimers bind vitamin D response
elements (VDREs) in target gene promoters and recruit coactiva-
tor proteins to modulate target gene transcription. 1,25(OH)2D3 is
a key regulator of calcium and phosphate homeostasis and bone
metabolism. In addition, 1,25(OH)2D3 has potent antiproliferative
and prodifferentiating actions on various normal as well as can-
cerous cell types (reviewed in Dusso et al. [2005]). In the human
colon cancer cell line SW480-ADH, 1,25(OH)2D3 promotes differ-
entiation by inducing the invasion suppressor E-cadherin and by
stimulating the translocation of b-catenin from the nucleus and
the cytosol to the plasma membrane. In addition, ligand-bound
VDR interferes with Wnt/b-catenin signaling by competing with
T cell transcription factor (TCF)-4 for b-catenin binding and asChemistry & Biology 15, 1029–such by reducing the pool of transcriptionally active TCF-4/b-
catenin complexes and their target genes, such as the c-Myc
oncogene (Palmer et al., 2001). The drawbacks for the use of
1,25(OH)2D3 to treat hyperproliferative disorders such as colon
cancer are undesired calcemic effects. Therefore, structural an-
alogs of 1,25(OH)2D3 have been designed to obtain a dissociation
between antiproliferative/prodifferentiating action and calcemic
effects. We have previously described the synthesis and the ac-
tivity of the nonsteroidal analogs CD578, WU515, and WY1113 in
which the complete six-membered C-ring has been deleted
(Figure 1A) (Verstuyf et al., 2000; Wu et al., 2002a, 2002b) (see
Supplemental Data available online for biological activity). These
three analogs are fluorinated on the side chain, a modification
that makes 1,25(OH)2D3 analogs more resistant to metabolic
degradation by the 24-hydroxylase (CYP24) enzyme. Here we
show that CD578, WU515, and WY1113 have a more potent pro-
differentiating action on human SW480-ADH colon cancer cells
than 1,25(OH)2D3. Behind this we found an increased VDR-based
transactivating potency and a stronger induction of the interac-
tion between VDR and coactivators SRC-1, TIF2, and DRIP205.
In addition, CD578, WU515, and WY1113 are more potent than
1,25(OH)2D3 in inhibiting b-catenin transcriptional activity. Coc-
rystallization of analog CD578 with the zebrafish (z)VDR and an
LXXLL-motif containing SRC-1 peptide revealed that the side
chain fluorine atoms on analog CD578 make additional contacts
with activation helix 12 (H12) of the VDR and with the loop be-
tween H11 and H12. These additional contacts stabilize the
active conformation of VDR and consequently favor coactivator
recruitment, which can explain the increased potency of the
analog.
RESULTS AND DISCUSSION
Increased Prodifferentiating Action of Analogs CD578,
WU515, and WY1113
In response to 1,25(OH)2D3, human SW480-ADH colon cancer
cells underwent epithelial differentiation characterized by an
increased adhesiveness and the formation of compact epitheli-
oid cell islands. The fluorinated, nonsteroidal analogs CD578,
WU515, and WY1113 induced the same morphological changes
as 1,25(OH)2D3, albeit at significantly lower doses. At 10
9 M,
there was no obvious effect of 1,25(OH)2D3, whereas a clear1034, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1029
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H12 Stabilization by Fluorinated Vitamin D AnalogsFigure 1. Chemical Structure of 1,25(OH)2D3 and Analogs and their Prodifferentiating Effects on SW480-ADH Colon Cancer Cells
(A) Chemical structure of the fluorinated nonsteroidal D-ring analogs CD578, WU515, and WY1113.
(B) Differentiation of SW480-ADH cells demonstrated by phase-contrast micrographs of SW480-ADH cells treated with 1010 or 109 M of each compound for
3 days. A representative experiment is shown. Scale bar = 40 mm.
(C) Western blotting analysis of the expression of E-cadherin, c-Myc, and b-actin (loading control) in SW480-ADH cells at 48 h of treatment with the indicated
doses of each compound. A representative experiment is shown.1030 Chemistry & Biology 15, 1029–1034, October 20, 2008 ª2008 Elsevier Ltd All rights reserved
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H12 Stabilization by Fluorinated Vitamin D AnalogsFigure 2. Effects of 1,25(OH)2D3 and Analogs on b-Catenin/TCF and
VDR Transcriptional Activity
(A) SW480-ADH cells were transfected with the wild-type (TOP-flash) or
mutated (FOP-flash) b-catenin-TCF-responsive reporter plasmids and then
treated with 1,25(OH)2D3 or each analog (10
7 M) for 48 h. Mean values
(TOP/FOP ratio, expressed as percentages of vehicle-treated cells) ± stdev
obtained in three experiments using triplicates are shown. *Inhibition different
from inhibition by 1,25(OH)2D3 at the same dose according to Student’s t test
(p < 0.05).
(B) SW480-ADH colon cancer cells were transfected with a construct contain-
ing the Firefly luciferase gene under the control of four copies of a direct repeat
3 (DR3) VDRE. After 48 h incubation in the presence or absence of the indi-
cated doses of 1,25(OH)2D3 or analogs, luciferase activities were measured
and normalized as described in the Supplemental Data. Bars represent fold in-
crease ± standard deviation in normalized luciferase activity for 1,25(OH)2D3-
or analog-treated cells as compared with vehicle-treated cells. *Fold increase
different from fold increase for 1,25(OH)2D3 at the same dose according toChemistry & Biology 15, 1029–morphological change was observed for CD578, WU515, and
WY1113. Even at 1010 M, WU515 and WY1113 had a strong
prodifferentiating action (Figure 1B). The higher differentiating
action of the three analogs correlated with an increased potency
to induce expression of the invasion suppressor E-cadherin and
a more pronounced repression of the c-Myc oncogene. When
compared with 1,25(OH)2D3, the dose-dependent induction of
E-cadherin protein expression by CD578, WU515, and
WY1113 was 100- to 1000-fold stronger (Figure 1C; see Supple-
mental Data for densitometric quantification). To obtain the same
degree of c-Myc repression as for 1,25(OH)2D3 at 10
8 M, 100-
fold lower doses were required for CD578 and WU515. Even at
1011 M, WY1113 inhibited c-Myc expression more strongly
than 1,25(OH)2D3 at 10
8 M (Figure 1C). The c-Myc oncogene
is a target for b-catenin/TCF-4 at the end of the Wnt/b-catenin
signaling pathway. We therefore examined the potency of
1,25(OH)2D3 and the analogs to inhibit the transcriptional activity
of b-catenin/TCF complexes and found that CD578, WU515, and
WY1113 prevented with higher efficiency than 1,25(OH)2D3 the
endogenous b-catenin present in the nucleus from inducing a
b-catenin/TCF-responsive reporter construct. At 109 M, the in-
hibition of b-catenin transcriptional activity caused by CD578,
WY1113, and WU 515 was 32%, 49%, and 53%, respectively,
versus 15% for 1,25(OH)2D3. At 10
8 M, suppression of b-cate-
nin transcriptional activity by each of the three analogs was at
least 50% versus 16% for 1,25(OH)2D3 (Figure 2A). Similarly, at
108 and 109 M, CD578, WU515, and WY1113 were signifi-
cantly stronger (at least 1.8-fold or higher) inducers of VDR tran-
scriptional activity than 1,25(OH)2D3 (Figure 2B). The magnitude
of the differences between 1,25(OH)2D3 and the analogs in this
last assay was more modest in comparison with the protein
expression data mentioned above probably due to the different
nature of the two approaches (endogenous proteins versus re-
porter gene assay). The increased transcriptional activity of the
analogs correlated with stronger induction of VDR-coactivator
interaction as was shown by mammalian two-hybrid assays
with VP16-fused VDR and GAL4-DNA binding domain-fused
SRC-1; tenfold lower doses of CD578, WU515, and WY1113 suf-
ficed to obtain the same level of VDR-SRC-1 interaction induced
by 107 M 1,25(OH)2D3 (Figure 2C). Similar results were obtained
for the interactions VDR-TIF2 and VDR-DRIP205 (see Supple-
mental Data). These results show that stronger biological activity
of CD578, WU515, and WY1113 as compared with the natural
VDR ligand is paralleled by a higher potency to induce VDR-
based transactivation and to induce binding of coactivators to
the VDR. It has previously been shown that biological activity
highly correlates with the analog’s ability to induce VDR-coacti-
vator interactions (Yamamoto et al., 2003). This strong correla-
tion may be partially accounted for by pharmacokinetic
Student’s t test (p < 0.05). A representative experiment performed in triplicate
is shown.
(C) Induction of VDR-SRC-1 interaction by transfecting human colon
cancer Caco-2 cells with pVPVDR, pSG424-SRC1-NIR, pG5-LUC, and
pcDNA3.1()/Myc-His/lacZ for normalization and treated with the different
ligands at the indicated doses. A representative experiment of three indepen-
dent experiments is shown. Data are the mean ± standard deviation of tripli-
cate samples. *Relative luciferase units (RLU) different from RLU for
1,25(OH)2D3 at the same dose according to Fisher’s LSD multiple-comparison
test (a = 0.05).1034, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1031
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H12 Stabilization by Fluorinated Vitamin D Analogsdifferences between analogs and 1,25(OH)2D3. An issue to take
into account is the increased resistance of an analog to catabo-
lism. Some analogs are designed in such a way that they with-
stand 24-hydroxylase (CYP24)-mediated catabolism better
than 1,25(OH)2D3. CD578 and WU515 have a 23-yne structure,
whereas WY1113 has a 20-epi configuration; two modifications
that are known to result in higher resistance to CYP24-mediated
degradation. Moreover, all three analogs are fluorinated at the
end of the side chain. Fluorination makes the side chain less sus-
ceptible to degradation, because C-F bonds better withstand
homolytic cleavage and radical oxidation (Imanishi et al.,
1999). Taken together, the differences in VDR-coactivator inter-
actions might be a mere reflection of differences in metabolism
between 1,25(OH)2D3 and the analogs. To exclude this possibil-
ity, 2 3 107 M VID400, a selective inhibitor of CYP24 (Schuster
et al., 2001), was used in the mammalian two-hybrid assays with
VDR and coactivators (see Supplemental Data). The addition of
VID400 increased the potency of 1,25(OH)2D3 to induce VDR-
coactivator interaction approximately twofold. As expected,
the interaction induced by CD578, WU515, and WY1113 hardly
changed after addition of VID400 but remained significantly
stronger in comparison with the interaction induced by
1,25(OH)2D3.
Cocrystallization of the CD578-zVDR- SRC-1 Complex
To gain more insight into the molecular mechanism underlying
the increased activity of the analogs, we cocrystallized CD578
together with the zebrafish (z)VDR and an SRC-1 coactivator
peptide with the second LXXLL-motif containing NR box. The
crystals of wild-type zVDR ligand-binding domain (LBD) bound
to CD578 and SRC-1 peptide were obtained under similar con-
Figure 3. Conformation of the VDR-Bound CD578 Analog
(A) The analog CD578 is shown in its Fo-Fc electron density omit maps
contoured at 3.0s. The ligand is shown in stick representation with carbon,
oxygen, and fluorine atoms in green, red, and sky blue, respectively.
(B) Stereo view of the conformation of the bound ligands. CD578 (green) and
1,25(OH)2D3 (pink) are shown in stick representation after superimposed
VDR complexes.1032 Chemistry & Biology 15, 1029–1034, October 20, 2008 ª2008ditions as for zVDR-1,25(OH)2D3 (Ciesielski et al., 2007). The
zVDR LBD was used to crystallize complexes to circumvent
the packing constraints of the unique crystal form obtained for
the mutant human (h)VDR in which the 62 residues containing
insertion region between helices H2 and H3 has been deleted
(Rochel et al., 2000). We have previously shown that the struc-
ture of zVDR LBD is similar to the structure of hVDR LBD in com-
plex with 1,25(OH)2D3 (Rochel and Moras, 2006). The structure
of the zVDR complex was refined at a resolution of 2.7 A˚. After
refinement of the protein alone, the map showed an unambigu-
ous electron density to fit the ligand (Figure 3A). The zVDR
LBD in complex with CD578 analog adopted the canonical active
conformation observed for agonist-bound receptors and was
similar to that of the zVDR-1,25(OH)2D3 and to the mutant
hVDR-1,25(OH)2D3 complexes (Rochel and Moras, 2006). As in
the zVDR-1,25(OH)2D3 complex, the insertion region between
helices H2 and H3 was not visible in the electron density map,
which reflects its disorder. Upon agonistic ligand binding in its
LBD pocket, the VDR releases corepressors and repositions its
C-terminal helix H12 in such a way that it closes off the pocket.
This event favors coactivator interaction because exact position-
ing of H12 as a ‘‘lid’’ on top of the LBD pocket gives rise to a
charge clamp between residues Glu446 [hGlu420] and Lys274
[hLys246] into which coactivators can dock through conserved
LXXLL motifs (Vanhooke et al., 2004). In comparison to the
zVDR-1,25(OH)2D3 complex, the position and conformation of
the activation helix H12 in the zVDR-CD578 complex was strictly
maintained. The SRC-1 peptide forms an amphipatic a-helix in-
teracting with the hydrophobic cleft formed by H3 and H4. These
interactions are similar to those described for other nuclear re-
ceptors (Darimont et al., 1998). In particular Glu446 [hGlu420]
from H12 forms hydrogen bonds with the backbone amide nitro-
gen of Ile689 and Leu690 of the LXXLL motif. At the other end,
Lys274 [hLys246] from H3 forms a hydrogen bond to the main
chain oxygen of Leu694. When compared with the structure of
the zVDR-1,25(OH)2D3 complex, the atomic models of zVDR
bound to CD578 showed rms deviation of 0.29 A˚ on all Ca-
atoms. The ligand was buried in the predominantly hydrophobic
pocket that is conserved in all complexes. The size of CD578
ligand is 380 A˚3 compared with 396 A˚3 for 1,25(OH)2D3. The vol-
ume of the ligand binding cavity is 693 and 687 A˚3, and CD578
and 1,25(OH)2D3 occupy 54.8% and 57.6% of the pocket,
respectively. The A- and secoB-rings (Figure 1A) of CD578 pre-
sented conformations similar to that of 1,25(OH)2D3 (Figure 3B).
The D ring of CD578 was shifted by 0.5 A˚ because of the modi-
fied side chain. The distance between the 1-OH and 25-OH
groups varied from 16.1 A˚ to 15.4 A˚ for zVDR-CD578 and
zVDR-1,25(OH)2D3, respectively. The interactions between the
receptor and the ligand (79 interactions for zVDR-CD578, 71
interactions for zVDR-1,25(OH)2D3 at a distance cutoff of 4.0 A˚)
involved both hydrophobic and electrostatic contacts. The
same conformations of the residues which form the LBD pocket
were observed. The absence of the C ring in CD578 induced loss
of a contact between Leu258 [hLeu230] and the atom C11 of
1,25(OH)2D3 and decreased interactions with Trp314 [hTrp286]
(8 interactions instead of 10 with atoms of Trp314 at a cutoff of
4 A˚). Furthermore, the indole group of Trp314 [hTrp286] was
shifted by 0.6 A˚ closer to the ligand to fill the space created by
the absence of the C ring (Figure 4A). The C9 atom of CD578Elsevier Ltd All rights reserved
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H12 Stabilization by Fluorinated Vitamin D Analogsmade a new contact with Leu341 [hLeu313] at 3.3 A˚. Most inter-
estingly, CD578 interacted through its fluorine atoms with Val444
[hVal418] and Phe448 [hPhe422] of H12 and with Leu440
[hLeu414] of the loop H11-H12 at a distance of 3.5, 3.6, and
3.3 A˚, respectively. In contrast, in the zVDR-1,25(OH)2D3 com-
plex, the ligand made no contacts with the activation helix H12
within a distance cutoff of 4.0 A˚ (the closest distance is 4.1 A˚
for Val444 [hVal418]). The canonical hydrogen bonds formed
between the hydroxyl groups of the ligands and the LBD are con-
served. The 25-OH group of CD578 interacted with His333
[hHis305] in the same way as the corresponding hydroxyl group
of 1,25(OH)2D3, whereas the hydrogen bond formed with His423
[hHis397] was weaker (3.2 A˚ instead of 2.8 A˚) but was compen-
sated for by an interaction again with a fluorine atom (Figure 4B).
As a consequence of the stronger contacts with and the conse-
quent stabilization of H12 in the zVDR-CD578 complex, the co-
activator SRC-1 peptide made additional interactions (80 inter-
actions with VDR in the zVDR-CD578 complex compared with
68 in the zVDR-1,25(OH)2D3 complex at a distance cutoff of
4.0 A˚). Docking of WU515 and WY1113 (data not shown) indi-
cated similar additional and stronger interactions with activation
H12 of the VDR. These structural data raise the question about
whether the analogs’ increased potency to induce VDR/b-cate-
nin interaction (and subsequent inhibition of b-catenin/TCF tran-
scriptional activity) is also a consequence of H12 stabilization
through the side chain fluorine atoms. A recent study hypothe-
sized that b-catenin binding occurs at an intermediate stage
Figure 4. Close-up View of 1,25(OH)2D3 and Analog CD578 in the
VDR LBD Pocket
(A) Stereo views around D ring.
(B) 25-OH of CD578 (green) and 1,25(OH)2D3 (pink) in the VDR LBD pocket.
Carbon atoms of the residues, which are closer than 4.0 A˚ and important for
comparison, are shown in light green and white for CD578 and 1,25(OH)2D3,
respectively. Nitrogen, oxygen, and fluorine atoms are shown in blue, red,
and sky blue, respectively. Dotted lines represent hydrogen bonds of the
CD578 complex.Chemistry & Biology 15, 1029–1between ligand-binding and the creation of the correct VDR con-
formation required for docking of ‘‘classical’’ coactivators (Shah
et al., 2006). Additional modeling studies are required to deter-
mine if side chain fluorine atoms can have a stabilizing effect
on this intermediate stage as well.
SIGNIFICANCE
1,25(OH)2D3 has strong antiproliferative and prodifferentiat-
ing actions on a range of cell types, including cancer cells.
Actual use of 1,25(OH)2D3 to treat hyperproliferative disor-
ders is hampered by calcemic effects, hence the continuous
development of chemically modified analogs of 1,25(OH)2D3
with a strong dissociation between antiproliferative/prodif-
ferentiating and calcemic actions. Side chain fluorination
can increase an analog’s biological activity by protecting it
from metabolic degradation by the 24-hydroxylase enzyme.
This study shows that the side chain fluorine atoms of the
nonsteroidal 1,25(OH)2D3 analogs CD578, WU515, and
WY1113 contribute to the increasedprodifferentiating action
oncolon cancer cells not only byprotecting the analogs from
metabolic degradation but also by increasing the stability of
activation helix 12 (H12) of the vitamin D receptor through in-
creased interactions with specific residues of H12. These
Table 1. Data Collection and Refinement Statistics
Data Processing
Resolution (A˚) 502.7 (2.802.70)
Crystal space group P6522
Cell parameters (A˚) a = b = 66.1; c = 265.6
Unique reflections 10,290 (990)
Mean redundancy 17.3
Rsym (%)
a 11.1 (29.9)
Completeness (%) 99.7 (100)
Mean I/s (%) 30.3 (13.4)
Refinement
Number of protein atoms 2010
Number of ligand atoms 33
Number of water molecules 62
Number of magnesium ion 1
RMSD bond length (A˚)b 1.106
RMSD bond angles ()b 0.006
Rcryst (%)
c 22.6
Rfree (%)
d 28.6
Ramachandran plot (%)
Core 90.2
Allow 9.8
Values in parentheses correspond to the highest resolution shell.
aRsym(I) = ShklSi jIhkl, i <Ihkl>j /ShklSi jIhkl, ijwith <Ihkl> the mean intensity
of the multiple Ihkl, i observations for symmetry-related reflections.
b Root-mean-squared deviations (RMSD) are given from ideal values.
cRcryst = S hkl jFobs  Fcalcj / S hkl jFobsj, where Fobs and Fcalc are the
observed and calculated structure factor amplitudes, respectively.
d Calculated using a random set containing 5% of observations that were
not included throughout refinement.034, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1033
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H12 Stabilization by Fluorinated Vitamin D Analogsfindings contribute to a better understanding of howspecific
chemicalmodificationsof 1,25(OH)2D3can lead todesiredbi-
ological activity and canbe of great value in the development
of new 1,25(OH)2D3 analogs with possible therapeutic appli-
cations and—by extension—in the search for novel selective
nuclear receptor modulators.
EXPERIMENTAL PROCEDURES
Reagents
1,25(OH)2D3 was obtained from J. P. van de Velde (Solvay, Weesp, The
Netherlands). Synthesis of the 17-methyl-19-nor-21-nor-23-yne-26,27-F6-
1,25(OH)2D3-D-ring analog (CD578), the 23-yne-26,27-F6-1,25(OH)2D3-D-ring
analog (WU515) and the 17-methyl-19-nor-20-epi-26,27-F6-1,25(OH)2D3-
D-ring analog (WY1113) has been described previously (Verstuyf et al., 2000;
Wu et al., 2002a, 2002b). The 24-hydroxylase inhibitor VID400 was obtained
from A. Stu¨tz (Novartis, Vienna, Austria).
Western Blotting
Western blotting was performed as described previously (Palmer et al., 2001).
Antibodies used were mouse monoclonal anti-E-cadherin (Transduction Lab-
oratories), mouse monoclonal anti-c-Myc, and goat polyclonal anti-b-actin
(Santa Cruz Biotechnology). Blots were developed using the ECL detection
system (G.E. Healthcare-Amersham).
Transactivation and Mammalian Two-Hybrid Assays
Detailed information about transactivation assays and mammalian two-hybrid
assays can be found in the Supplemental Data.
Crystallography of Zebrafish (z)VDR-CD578-SRC-1 Complex
Details on expression, purification, crystallization, and subsequent X-ray crys-
tallography, data collection and processing can be found in Table 1 and in
Supplemental Data. The residue numbers in the text correspond to the
zVDR sequence; the corresponding human residue numbers are given within
brackets [hAAxxx].
ACCESSION NUMBERS
The PDB accession number for the coordinates of the zVDR-CD578-SRC-1
complex is 3DR1.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, three figures, and one table and can be found with this
article online at http://www.chembiol.org/cgi/content/full/15/10/1029/DC1/.
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